The impact of obesity on hypertension and diabetes control following healthy Lifestyle Intervention Program in a developing country setting

Aliakbar Tavassoli\textsuperscript{a}, Mojgan Gharipour\textsuperscript{b,}\textsuperscript{a}, Nafiseh Toghianifar\textsuperscript{c}, Nizal Sarrafzadegan\textsuperscript{d}, Alireza khosravi\textsuperscript{e}, Behzad Zolfaghari\textsuperscript{f}, Sonia Zarfeshani\textsuperscript{b}

Abstract

BACKGROUND: The aim of this study was to evaluate the impact of obesity and overweight on diabetes mellitus (DM) and hypertension (HTN) control in a healthy lifestyle intervention program in Iran.

METHODS: Within the framework of the Isfahan Healthy Heart Program (IHHP), a community trial that was conducted to prevent and control cardiovascular disease and its risk factors, two intervention counties (Isfahan and Najafabad) and one reference county (Arak) were selected. Demographic information, medical history, anti-diabetic and anti-hypertensive medications use were asked by trained interviewers in addition to physical examination and laboratory tests for 12514 adults aged more than 19 years in 2001 and were repeated for 9572 adults in 2007.

RESULTS: In women, the frequency of HTN control change significantly neither in normal weight nor in those with high body mass index (BMI), waist circumference (WC) or waist to hip ratio (WHR). In men, the frequency of HTN control was only significant among those with high WHR, whereas the interaction between changes in intervention compared to reference area from 2001 to 2007 was significant in men with normal or high WC or WHR. In intervention area, the number of women with high BMI who controlled their DM increased significantly from 2001 to 2007 (p = 0.008), however, this figure decreased in men. In reference area, obesity indices had no significant association with DM control. The percentage of diabetic subjects with high WC who controlled their DM decreased non-significantly in intervention area compared to reference area in 2007. A non-significant increase in controlled DM among men and women with high WHR was observed between intervention and reference areas.

CONCLUSIONS: Our lifestyle interventions did not show any improving effect on HTN or DM control among obese subjects based on different obesity indices. Other lifestyle intervention strategies are suggested.

KEYWORDS: Hypertension, Diabetes, Obesity, Control, Prevention, Iran.

Obesity and overweight are now considered to be serious health problems, with an increasing prevalence worldwide,\textsuperscript{1} such that the World Health Organization (WHO) reported overweight and obesity to be a rising epidemic.\textsuperscript{2} Previous studies in Iran showed a high prevalence of obesity.\textsuperscript{3} Overall, 11.2% of men and 28.1% of women are obese and 36.6% of Iranian men and 35.9% of women are overweight.\textsuperscript{4,5}
Obesity is an independent risk factor for a number of chronic diseases, including hypertension (HTN), Diabetic Mellitus (DM), cardiovascular disease (CVD) and some cancers. It seems that obesity, DM and HTN are known to increase in both developed and developing populations. Decrease in adiposity is one of the most effective preventive measures in decreasing not only the overall cardiovascular risk but also blood pressure (BP) and increasing DM control.

Many studies suggested that lifestyle modification has great potential to reduce obesity and other related cardiovascular risk factors. Some have recently shown effects of lifestyle modification on control of BP and decrease in the incidence of DM in individuals with impaired glucose tolerance. Efforts which focus on changing lifestyle can lead to change people’s attitude, behavior and practice in the whole population as well as high risk groups.

In this regard, Isfahan Healthy Heart Programme (IHHP), a community-based intervention program, was designed and implemented to prevent CVD and control its related risk factors by promoting healthy lifestyle. IHHP used both the general population and high risk intervention strategies for CVD prevention. In this study, we intended to evaluate the impact of obesity and overweight on DM and HTN control following IHHP interventions.

**Methods**

IHHP was conducted in three counties, Isfahan and Najaf-Abad as intervention areas and Arak as reference area, all located in central Iran. Arak, placed 375km north-west of Isfahan was selected because of the similarity with the intervention areas regarding socio-economic, demographic and health profile and good cooperation. Started in 2000, the programme was consisted of three phases, the first as baseline survey for situational analysis, the second included implementing interventional activities in the intervention areas (late in 2001-2005), and the third as post-intervention survey (2007) to evaluate the programme outcomes. Having resided for more than five years in these cities, not being pregnant for females and being mentally healthy were the criteria for participating in this study. After the baseline survey, a five-year intervention programme was started both in urban and rural areas of Isfahan and Najaf-Abad. Arak was evaluated during this period as the reference area.

During the intervention phase, we took a systematic approach to undertake process, impact and outcome evaluation. Interventional activities were designed in ten projects based on different target groups to address the whole community and specific target populations and subjects in an integrated package. The main themes of interventions included healthy nutrition, tobacco control, physical activity and coping stress. Public and health professionals training, intersectoral collaboration and legislation were among men strategies. Specific educational companion for hypertensive and diabetic patients were implemented.

IHHP team conducted the baseline survey on 12514 adults, aged ≥ 19 years in 2000-2001 and carried out the same survey on 9572 adults in 2007 as outcome evaluation. Multistage random sampling was used to select participants in both studies in intervention and reference areas. The sample distribution was consistent with sex and age distribution in the population of three counties. Written informed consents were obtained from all subjects. The methods were in accordance with ethical standards of the Ethical Committee of Isfahan University of Medical Sciences. Full details of the program have been reported elsewhere.

Initially, a questionnaire was completed at each subject’s home by trained interviewers. It contained demographic information, smoking, nutritional and physical activity habits, medical history, and consumption of relevant medications especially anti-diabetic and anti-hypertensive agents. Subsequently, participants were invited to certain health centers, where physical examination and blood sampling after 12 to 14 hour fasting were carried out. Subjects were weighed with light clothes
and no shoes, and their height was measured and body mass index (BMI) was calculated.\textsuperscript{15} Waist circumference (WC) was measured at the midpoint between the iliac crest and the lower margin of the rib to the nearest half-centimeter. Hip circumference (HC) was measured and waist to hip ratio (WHR) was calculated too.\textsuperscript{15} The BP was measured twice with a standardized method, with the subjects in a sitting position, and the average BP was taken into consideration.\textsuperscript{12}

In addition to fasting plasma glucose (FPG), 2-hour plasma glucose (2hpp) after consumption of 75 gram of glucose was also measured. Serum lipids, including total cholesterol (TC), triglyceride (TG), and HDL-cholesterol (HDL-C) were measured using enzymatic method. LDL cholesterol (LDL-C) was measured using Friedwald formula.\textsuperscript{13} All blood sampling procedures were performed in the central laboratory of the Isfahan Cardiovascular Research institute, which is standardized with the Department of Epidemiology, K.U. Leuven, Belgium and Lab Quality External Assessment Services, Helsinki, Finland. Both quality controls showed good correlations.

The subjects of the present study were either hypertensives or diabetics who were selected among all participants of the IHHP study from the baseline and the post-intervention surveys. Controlled HTN was defined as SBP < 140 mmHg or DBP < 90 mmHg and currently taking antihypertensive medications.\textsuperscript{16} Controlled DM was defined as FPG < 140 mg/dl and currently taking anti-diabetic treatment.\textsuperscript{16} Normal weight was defined as BMI < 25 kg/m$^2$ and overweight plus obese as BMI ≥ 25 kg/m$^2$.\textsuperscript{17} Abdominal obesity was defined as WC ≥ 102 cm for men and ≥ 88 cm for women. Gender specific cut-off points of ≥ 0.95 cm and ≥ 0.80 cm for WHR were used for men and women respectively.\textsuperscript{15}

### Statistical Analysis

Data entry was carried out using EPI info\textsuperscript{TM}. All data were analyzed by SPSS (SPSS Inc, Chicago, IL, USA; Version 15). The averages were reported as Mean ± SD and frequencies as percents. For all analyses, statistical significance was assessed at a level of 0.05 (2-tailed). T-test and Mann-Whitney tests were used to compare continuous variables. The groups were compared using the chi-square test (or Fisher’s exact test if required) for the categorical variables. In addition, area (intervention vs. reference)* time (2001 vs. 2007) interaction term was tested in logistic regression model. Differences between 2001 and 2007 values were compared between intervention and reference areas among males and females separately using two-way ANOVA.

### Results

The mean values of risk factors in men and women with controlled hypertension in 2001 and 2007 are presented in Table 1. In the intervention area, from 2001 to 2007 the WC declined significantly among controlled hypertensive women (102.22 ± 12.77 vs. 98.30 ± 11.36), and non-significantly among men (99.17 ± 8.49 vs. 97.82 ± 10.14). However, it increased significantly among women (95.94 ± 13.55 vs. 99.92 ± 11.898) and men (92.5 ± 10.75 vs. 98.28 ± 10.75) in the reference area. In women, WHR did not show any difference from 2001 to 2007 in intervention area, however, it increased significantly in reference area ($p < 0.05$). No significant change was seen regarding lipoproteins level in intervention and reference areas.

Table 2 shows the basic characteristics of controlled diabetic men and women in 2001 and 2007. There was no significant difference in the mean age in both sexes. In the intervention area, WC decreased in women; whereas it increased significantly among men and women in reference area. No significant change was observed in men or women regarding systolic or diastolic BP, TC, TG, HDL-C and LDL-C.

The frequency of HTN control by obesity indices in 2001 and 2007 are presented in table 3. In women, the frequency of HTN control did not change significantly in normal weight or in those with high BMI, WC or WHR. The $p$-value for interaction was significant only for controlled HTN in women with high WC. In men, the frequency of HTN control was only
Table 1. Basic Characteristics of controlled hypertensive men and women following Isfahan Healthy Heart Program in intervention and reference areas in 2001 and 2007

|                      | Women                          | Men                          | Interaction p-value |
|----------------------|--------------------------------|------------------------------|---------------------|
|                      | Intervention Area Mean(SD)     | Reference area Mean(SD)      |                     |
|                      | 2001 N = 82                   | 2007 N = 116                |                     |
|                      | 2001 N = 80                   | 2007 N = 97                 |                     |
|                      | 2001 N = 24                   | 2007 N = 51                 |                     |
|                      | 2001 N = 39                   | 2007 N = 50                 |                     |
| Age (Year)           | 57.31 (14.32)                 | 57.68 (13.19)               | 0.82                |
|                      | 57.85 (12.63)                 | 57.55 (15.45)               |                     |
|                      | 57.17 (13.52)                 | 58.98 (12.26)               |                     |
|                      | 58.17 (16.12)                 | 58.82 (16.71)               |                     |
|                      | 0.82                          | 0.73                        |                     |
| BMI (Kg/m$^2$)       | 28.44 (4.71)                  | 29.05 (4.32)                | 0.003               |
|                      | 27.32 (4.38)                  | 27.60 (4.75)                |                     |
|                      | 27.20 (3.59)                  | 27.40 (3.26)                |                     |
|                      | 27.59 (3.68)†                 | 26.75 (4.46)                |                     |
| WC (cm)              | 102.22 (12.77)                | 98.30 (11.36)*              | 0.049               |
|                      | 95.94 (13.55)†                | 99.92 (11.898)*†            |                     |
|                      | 99.17 (8.49)                  | 97.82 (10.14)               |                     |
|                      | 92.5 (10.75)†                 | 98.28 (12.21)*              |                     |
| WHR (cm)             | 0.96 (0.07)                   | 0.96 (0.09)                 | 0.07                |
|                      | 0.93 (0.10)†                  | 0.97 (0.08)*                |                     |
|                      | 0.9 (0.06)                    | 0.94 (0.06)                 |                     |
|                      | 0.93 (0.11)                   | 0.96 (0.09)                 |                     |
| FPG (mg/dl)          | 99.99 (45.81)                 | 96.55 (24.26)               | 0.017               |
|                      | 85.85 (20.62)†                | 97.87 (28.21)*              |                     |
|                      | 92.67 (25.01)                 | 110.01 (41.21)*             |                     |
|                      | 103.47 (57.48)                | 96.98 (26.13)               |                     |
| Total Cholesterol    | 239.67 (51.06)                | 217.12 (41.69)*             | 0.71                |
| (mg/dl)              | 228.97 (52.07)                | 210.09 (43.25)*             |                     |
|                      | 218.54 (65.04)                | 203.74 (42.94)              |                     |
|                      | 208.34 (69.59)                | 199.78 (35.72)              |                     |
| Triglyceride         | 217.21 (109.39)               | 190.98 (166.26)             | 0.73                |
| (mg/dl)              | 188.42 (73.56)                | 170.56 (80.74)              |                     |
|                      | 219.29 (102.31)               | 197.63 (112.22)             |                     |
|                      | 207.84 (134.83)               | 202.20 (114.99)             |                     |
| hdl-c (mg/dl)        | 49.26 (9.93)                  | 46.54 (12.04)               | 0.98                |
|                      | 48.77 (9.86)                  | 46.11 (10.83)               |                     |
|                      | 46.37 (9.33)                  | 38.96 (10.62)*              |                     |
|                      | 44.50 (9.81)                  | 40.54 (11.69)               |                     |
| ldl-c (mg/dl)        | 147.70 (38.57)                | 132.18 (33.05)*             | 0.88                |
|                      | 143.21 (42.61)                | 128.93 (35.98)*             |                     |
|                      | 121.76 (47.33)                | 125.74 (32.86)              |                     |
|                      | 116.72 (46.30)                | 119.01 (30.99)              |                     |

BMI: Body Mass Index, WC: waist circumference, WHR: waist-to-hip ratio, FPG: Fasting plasma glucose, HDL-C: High Density Lipoprotein Cholesterol, LDL-C: Low Density Lipoprotein Cholesterol.
* Indicates p-value between 2001 and 2007 by t-test or Mann-Whitney test.
† Indicates p-value between intervention and reference areas in 2001 by t-test or Mann-Whitney test.
‡ Indicates p-value between intervention and reference areas in 2007 by t-test or Mann-Whitney test.
P-value for Interactions obtained from two-way ANOVA.
### Table 2. Basic Characteristics of controlled diabetic men and women following Isfahan Healthy Heat Program in intervention and reference areas in 2001 and 2007

|                      | Women          | Men            | Interaction P-Value | Reference area Mean(SD) | Reference area Mean(SD) | Interaction P-Value | Reference area Mean(SD) | Reference area Mean(SD) |
|----------------------|----------------|----------------|--------------------|------------------------|------------------------|--------------------|------------------------|------------------------|
|                      | Intervention Area | Reference Area |                   | 2001 N = 27 | 2007 N = 37 | 2001 N = 24 | 2007 N = 34 | 2001 N = 21 | 2007 N = 27 | 2001 N = 17 | 2007 N = 19 |
| **Age (Year)**       | 53.48 (13.74)   | 54.29 (12.99)  | 54.62 (12.91)      | 52.88 (9.97)           | 0.57                   | 55.14 (12.95) | 59.71 (13.06) | 55.76 (15.13) | 55.00 (13.21) | 0.38 |
| **BMI (Kg/m²)**      | 29.06 (5.10)    | 30.14 (3.61)   | 28.21 (4.67)       | 28.47 (3.62)           | 0.59                   | 27.91 (4.36)  | 26.71 (4.32)  | 27.38 (5.13)† | 25.98 (3.77) | 0.92 |
| **WC (cm)**          | 103.98 (10.78)  | 99.62 (11.33)  | 96.61 (13.96)†     | 102.21 (11.37)         | 0.031                  | 102.19 (14.37) | 95.52 (11.56) | 91.88 (13.20)† | 95.71 (7.99) | 0.07 |
| **WHR (cm)**         | 0.96 (0.06)     | 0.97 (0.09)    | 0.92 (0.07)        | 0.96 (0.098)           | 0.18                   | 0.96 (0.06)   | 0.95 (0.06)   | 0.91 (0.097)† | 0.93 (0.06) | 0.23 |
| **Systolic Blood Pressure (mmHg)** | 128.14 (22.67) | 125.07 (16.79) | 132.71 (22.24)    | 131.03 (29.58)         | 0.87                   | 133.81 (23.92) | 131.94 (23.43) | 135.88 (27.35) | 128.42 (20.55) | 0.59 |
| **Diastolic Blood Pressure (mmHg)** | 81.11 (14.71)  | 79.66 (11.72)  | 85.10 (2.97)       | 78.52 (12.40)*         | 0.28                   | 79.52 (13.52) | 78.31 (17.29) | 83.67 (11.89) | 78.02 (8.60) | 0.47 |
| **Total Cholesterol (mg/dl)** | 190.03 (75.87) | 177.24 (99.40) | 180.04 (88.82)    | 208.52 (109.32)        | 0.24                   | 208.61 (74.46) | 196.37 (158.11) | 225.47 (163.65) | 192.68 (130.24) | 0.73 |
| **Triglyceride (mg/dl)** | 224.19 (46.91) | 213.86 (44.59) | 206.58 (46.42)    | 223.23 (44.28)         | 0.11                   | 206.52 (41.94) | 185.37 (28.77)* | 203.53 (52.14) | 197.89 (30.63) | 0.36 |
| **hdl-c (mg/dl)**    | 53.48 (9.63)    | 44.72 (9.44)*  | 47.04 (9.34)†     | 45.09 (14.12)          | 0.1                    | 46.47 (9.54)  | 37.14 (9.91)*  | 48.18 (12.18) | 42.47 (12.54) | 0.46 |
| **ldl-c (mg/dl)**    | 130.37 (38.93)  | 133.37 (35.86) | 128.42 (43.48)    | 136.92 (35.94)         | 0.71                   | 120.61 (43.55) | 112.78 (24.99) | 106.50 (29.16) | 118.02 (31.22) | 0.2 |

**BMI**: Body Mass Index, WC: waist circumference. WHR: waist-to-hip ratio, HDL-C: High Density Lipoprotein Cholesterol, LDL-C: Low Density Lipoprotein Cholesterol.

* Indicates p-value between 2001 and 2007 by t-test or Mann-Whitney test.
† Indicates p-value between intervention and reference areas in 2001 by t-test or Mann-Whitney test.
‡ Indicates p-value between intervention and reference areas in 2007 by t-test or Mann-Whitney test.
P-value for Interactions obtained from two-way ANOVA.
Impact of obesity on hypertension and diabetes control

Tavassoli et al

Table 3: Sex-based hypertension controlled by obesity indices following Isfahan Healthy Heart Program in intervention and references areas in 2001 and 2007

| BMI kg/m² | Women | | | | Men | | | | Total | | |
|----------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
|          | Intervention Area | Reference area | Intervention Area | Reference area | Intervention Area | Reference area | Interaction | P-value | Interaction | P-value | Interaction | P-value |
|          | 2001 (n) (%) | 2007 (n) (%) | 2001 (n) (%) | 2007 (n) (%) | 2001 (n) (%) | 2007 (n) (%) |          |       |          |       |
| Normal   |       |       |       |       |       |       |       |       |       |       |       |       |
| WC (cm)  |       |       |       |       |       |       |       |       |       |       |       |       |
| Obese    |       |       |       |       |       |       |       |       |       |       |       |       |
| WHR (cm) |       |       |       |       |       |       |       |       |       |       |       |       |
| Obese    |       |       |       |       |       |       |       |       |       |       |       |       |

BMI: body mass index (kg/m²); Normal: < 25 kg/m²; Overweight and obese ≥ 25.

WC: waist circumference. Normal: in women 88 <, in men 102 <; Obese: in women 88 ≥, in men 102 ≥ cm.

WHR: waist-to-hip ratio. Normal: in women < 0.8, in men < 0.95; Obese: in women ≥ 0.8, in men 0.95 ≥ cm.

Controlled hypertension is defined as SBP < 140 mmHg or DBP < 90 mmHg or currently taking blood pressure medications.

* Indicates p-value between 2001 and 2007 by chi-Square or Fisher Exact test.

P-value for Interactions obtained from two-way ANOVA.

Significant among those with high WHR, whereas the p-value for interaction between changes in intervention compared to reference area from 2001 to 2007 was significant in men with normal or high WC or WHR.

The prevalence of controlled DM based on obesity indices in both intervention and reference areas at baseline and after interventions are presented in Table 4. In intervention area, the number of women with high BMI who controlled their DM increased significantly from 2001 to 2007 (p = 0.008), however, this figure decreased in men. In reference area obesity indices had no significant association with control of DM. The percentage of diabetic subjects with high WC who controlled their DM decreased non-significantly in intervention area compared to reference area in 2007. However, the p-value for interaction was significant in women. A non-significant increase in controlled DM among men and women with high WHR was observed between intervention and reference area.

Discussion

We observed non-significant changes in DM control in both sexes and HTN control in women following IHHP lifestyle intervention strategies. It can be explained by the non-significant changes in obesity in diabetic and hypertensive patients in intervention areas. On the contrary, our results demonstrated that WC decreased significantly in hypertensive women and non-significantly in hypertensive men in intervention area and increased significantly in both sexes in reference areas. In diabetic patients, WC decreased significantly in men in intervention area and increased...
Impact of obesity on hypertension and diabetes control
Tavassoli et al

Table 4. Sex-based diabetes controlled by obesity indices following Isfahan Healthy Heat Program in intervention and reference areas in 2001 and 2007

| Obesity indexes | Women | | Men | | Total | |
|-----------------|-------|-------|-------|-------|-------|-------|
|                  | intervention | reference | intervention | reference | intervention | reference |
|                  | 2001 n(%) | 2007 n(%) | 2001 n(%) | 2007 n(%) | 2001 n(%) | 2007 n(%) |
| BMI kg/m² | | | | | | |
| Normal | 7 (25.9) | 1 (2.7) | 9 (7.7) | 6 (17.6) | 12 (25.0) | 11 (17.2) |
| Obese | 20 (74.1) | 36 (97.3) | 17 (92.3) | 28 (82.4) | 36 (75.0) | 53 (82.8) |
| WC (cm) | | | | | | |
| Normal | 1 (3.7) | 7 (18.9) | 8 (33.3) | 4 (17.4) | 11 (52.4) | 18 (66.7) |
| Obese | 26 (96.3) | 30 (81.1) | 16 (66.7) | 19 (82.6) | 10 (47.6) | 9 (33.3) |
| WHR (cm) | | | | | | |
| Normal | 0 (0) | 0 (0) | 1 (4.2) | 0 (0) | 8 (38.1) | 10 (37.0) |
| Obese | 27 (100.0) | 37 (100.0) | 23 (95.8) | 2 (100.0) | 13 (61.9) | 17 (63.0) |

BMI: body mass index (kg/m²); Normal: < 25 kg/m²; Overweight and obese ≥ 25.
WC: waist circumference. Normal: in women < 88 cm, in men 102 cm; Obese: in women ≥ 88 cm, in men ≥ 102 cm.
WHR: waist-to-hip ratio. Normal: in women < 0.8, in men < 0.95; Obese: in women ≥ 0.8, in men ≥ 0.95 cm.

Controlled diabetes was defined as FPG < 140 mg/dl and currently taking anti-diabetic treatment.
* Indicates p-value between 2001 and 2007 by chi-Square or Fisher Exact test.
P-value for Interactions obtained from two-way ANOVA.

significantly in women living in reference area. Previous findings from IHHP showed no significant difference regarding BMI and significant decrease of WC between intervention and reference areas at the population level. It is known that weight loss can not only prevent or reverse blood pressure elevations but also have a favorable impact on other obesity-related CVD risk factors such as DM and hyperlipidemia.7,18,19 The interaction between body weight and HTN is very complex and both environmental and genetic factors are involved.20 Non-pharmacological treatments including lifestyle behaviours have an important role on HTN and DM control. We reported the impact of IHHP on lifestyle behaviours improvement before.10 Furthermore HTN control reached 15.8% following the implementation of IHHP interventions.21

Large studies have shown that central obesity has powerful relationship with CVD risk factors.22-24 Strong relationship between decreasing abdominal obesity and BP control has been reported specifically in women. In addition to lifestyle behaviors, it could be related to more complex interaction of female hormones with blood pressure. Although lifestyle behaviours have been improved following the implementation of IHHP interventions,10 however, HTN and DM control was not improved in patients with high BMI or WC who lived in intervention areas.

Conclusion
This study demonstrated that IHHP as a community trial targeting behaviours and CVD risk factors control did not show improving effect on HTN or DM control among obese subjects...
based on their different obesity indices. Our results suggested that other interventional strategies aiming at decreasing obesity might have an impact on HTN and DM control.

**Limitations**
As an important limitation, we acknowledge the low rate of controlled hypertensive and diabetic patients in the studied population. This might have affected the difference between two groups based on different obesity indices.

**Conflict of Interests**
Authors have no conflict of interests.

**Acknowledgment**
This study was a part of Isfahan Healthy Heart Program that was supported by Grant No. 31309304 from the Iranian Budget and Programming Organization in the Department of Health, Ministry of Health and Medical Education, Isfahan Cardiovascular Research Centre and Isfahan Provincial Health Centre, both affiliated to Isfahan University of Medical Sciences. We like to express our sincere thanks to the big team who conducted IHHP in Isfahan, Najafabad and Arak.

**Authors' Contributions**
AAT designed the study and drafted this manuscript, MG carried out the study and drafted the manuscript, NT drafted the manuscript and tables, NS designing the study, revising the manuscript procedures and drafting the manuscript, AK helped in designing the study, BZ helped in statistical analysis, SZ revising the manuscript. All authors read and approved the final manuscript.

**References**
1. Marcellini F, Giuli C, Papa R, Tirabassi G, Faloia E, Boscaro M, et al. Obesity and body mass index (BMI) in relation to life-style and psycho-social aspects. Arch Gerontol Geriatr 2009; 49(Suppl 1): 195-206.
2. Gyarfas I. Control of hypertension in the population. Strategies in affluent and developing countries. Clin Exp Hypertens 1996; 18(3-4): 387-97.
3. Hosseinpahah F, Barzin M, Eskandary PS, Mirmiran P, Azizi F. Trends of obesity and abdominal obesity in Tehranian adults: a cohort study. BMC Public Health 2009; 23; 9: 426.
4. Kelishadi R, Gharipour M, Sadri GH, Tavasoli AA, Amani A. Cardiovascular disease risk factors, metabolic syndrome and obesity in an Iranian population. East Mediterr Health J 2008; 14(5): 1070-9.
5. Sarrafzadegan N, Kelishadi R, Baghaei A, Hussein Sadri G, Malekafzali H, Mohammadifard N, et al. Metabolic syndrome: an emerging public health problem in Iranian women: Isfahan Healthy Heart Program. Int J Cardiol. 2008; 131(1): 90-6.
6. Rohrer JE, Anderson GJ, Furst JW. Obesity and pre-hypertension in family medicine: implications for quality improvement. BMC Health Serv Res 2007; 7: 212.
7. Khan A, Haq FU, Pervez MB, Saleheen D, Frossard PM, Ishaq M, et al. Anthropometric correlates of blood pressure in normotensive Pakistani subjects. Int J Cardiol 2008; 124(2): 259-62.
8. Lien LF, Brown AJ, Ard JD, Loria C, Erlinger TP, Feldstein AC, et al. Effects of PREMIER lifestyle modifications on participants with and without the metabolic syndrome. Hypertension 2007; 50(4): 609-16.
9. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344(18): 1343-50.
10. Sarrafzadegan N, Kelishadi R, Esmaillzadeh A, Mohammadifard N, Rabiei K, Roozafza H, et al. Do lifestyle interventions work in developing countries? Findings from the Isfahan Healthy Heart Program in the Islamic Republic of Iran. Bull World Health Organ 2009; 87(1): 39-50.
11. Baghaei AM, Sarrafzadegan N, Rabiei K, Gharipour M, Tavasoli AA, Shirani S, et al. How effective are strategies for non communicable disease prevention and control on high risk population in a developing country? Arch Med Sci 2010; 6(1): 24-31.
12. Sarraf-Zadegan N, Sadri G, Malek Afzali H, Baghaei M, Mohammadi Fard N, Shahrokhi S, et al. Isfahan Healthy Heart Programme: a comprehensive integrated community-based programme for cardiovascular disease prevention and control. Design, methods and initial experience. Acta Cardiologica 2003; 58(4): 309-20.

13. Sarraf-Zadegan N, Sadri G, Malek Afzali H, Baghaei. M, Mohammadi Fard N, Shahrokhi S. Isfahan Healthy Heart Program: Evaluation of comprehensive, community-based interventions for non-communicable disease. Prevention and Control J 2006; 2(2): 73-84.

14. Rabiei K, Kelishadi R, Sarrafzadegan N, Abedi HA, Alavi M, Heidari K, et al. Process evaluation of a community-based program for prevention and control of communicable disease in a developing country: The Isfahan Healthy Heart Program. BMC Public Health 2009; 9: 57.

15. Tavassoli AA, Gharipour M, Siadat ZD, Bahonar A, Sadary GH. Are obesogenic behavioral, socioeconomic and metabolic determinants different in Iranian men and women? Health Popul Nutr 2010; 28(6): 602-9.

16. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; Hypertension 2003; 42(6): 1206-52.

17. Esteghamati A, Gouya MM, Abbasi M, Delavari A, Alikhani S, Alaeddini F, et al. Prevalence of diabetes and impaired fasting glucose in the adult population of Iran: National Survey of Risk Factors for Non-Communicable Diseases of Iran. Diabetes Care 2008; 31(1): 96-8.

18. Green R, Kwok S, Durrington PN. Preventing cardiovascular disease in hypertension: effects of lowering blood pressure and cholesterol. QJM 2002; 95(12): 821-6.

19. Nanchahal K, Ashton WD, Wood DA. Association between blood pressure, the treatment of hypertension, and cardiovascular risk factors in women. J Hypertens 2000; 18(7): 833-41.

20. Khosravi A, Kiani Mehr G, Kelishadi R, Shirani S, Gharipour M, Tavassoli A, et al. The Impact of a 6-year Comprehensive Community Trial on the Awareness, Treatment and Control Rates of Hypertension in Iran: Experiences from the Isfahan Healthy Heart Program. BMC Cardiovasc Disord 2010; 10: 61.

21. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004; 89(6): 2583-9.

22. Kumanyika SK. The impact of obesity on hypertension management in African Americans. J Health Care Poor Underserved 1997; 8(3): 352-64; discussion 364-5.

23. Jones DW. What is the role of obesity in hypertension and target organ injury in African Americans? Am J Med Sci 1999; 317(3): 147-51.